• Takeda enters $1.04bn deal with Arrowhead Pharmaceuticals pharmaceutical-technology
    October 16, 2020
    Takeda has entered a collaboration and licensing agreement with Arrowhead Pharmaceuticals to develop an investigational drug, ARO-AAT, for the treatment of alpha-1 antitrypsin-associated liver disease (AATLD).
PharmaSources Customer Service